Diagnostic performance and factors influencing the accuracy of EUS-FNA of pancreatic neuroendocrine neoplasms

Susumu Hijioka1 · Kazuo Hara1 · Nobumasa Mizuno1 · Hiroshi Imaoka1 · Vikram Bhatia2 · Mohamed A. Mekky3 · Kenichi Yoshimura4 · Tsukasa Yoshida1 · Nozomi Okuno1 · Nobuhiro Hieda1 · Masahiro Tajika5 · Makoto Ishihara5 · Yasushi Yatabe6 · Yasuhiro Shimizu7 · Yasumasa Niwa5 · Kenji Yamao1

Received: 11 September 2015 / Accepted: 24 December 2015 / Published online: 14 January 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Background Multiple studies have investigated sampling adequacy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for pancreatic neuroendocrine neoplasms (pNENs). However, none have described the diagnostic performance of EUS-FNA for pNENs, or the influencing factors. The aim of this study was to evaluate the diagnostic accuracy of EUS-FNA, with post-operative pathological diagnosis as the gold standard, and factors predictive of inadequate EUS sampling.

Methods From 1998 to 2014, a total of 698 patients underwent pancreatic resection and 1455 patients underwent EUS-FNA sampling for pancreatic lesions. A total of 410 cases underwent both surgical resection and preceding EUS-FNA. Of these, 60 cases (49 true pNEN, nine non-diagnostic, two misdiagnoses) were included. We studied diagnostic performance of EUS-FNA and factors that were associated with failed diagnosis.

Results Of the 60 cases, EUS-FNA yield was 49 true-positive cases, two misdiagnoses, and nine non-diagnostic cases (including six suggestive cases). Sensitivity, specificity, and accuracy were 84.5, 99.4, and 97.3 %, respectively; including the six suggestive cases, diagnostic values were 94.8 % sensitivity (55/58), 99.4 % specificity (350/352), and 98.7 % accuracy (405/410). In multivariate analysis, sampling adequacy rates were significantly lower when lesions were located in the pancreatic head [odds ratio (OR) = 10.0] and in tumor-rich stromal fibrosis (OR = 10.45). Tumor size, needle type, tumor grading, presence of cystic component, and time period were not significant factors.

Conclusions EUS-FNA offers high accuracy for pNEN. However, location of the tumor in the pancreatic head and presence of rich stromal fibrosis negatively impacts sampling adequacy.

Keywords EUS-FNA · Pancreatic neuroendocrine neoplasms · Diagnosability

Introduction

Pancreatic neuroendocrine neoplasms (pNENs) are rare pancreatic tumors, estimated to comprise 2–3 % of all pancreatic neoplasms [1]. Recent progress in cross-sectional imaging has resulted in a substantial rise in detection rates for pNEN, even when small and asymptomatic. However, histological evidence is mandatory in addition to
suggestive imaging. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is now accepted as the primary sampling technique for pancreatic tumors [2, 3], with 83.3–93 % sampling adequacy rates [4–7]. The 2010 revised World Health Organization classification grades pNEN as NET-G1 G2 and NEC, based on Ki67 staining or mitosis rates [8]. Concordance rates between grading of pNENs by EUS-FNA and postoperative histology are reportedly within the range of 77–89.5 % [9–14]. We have previously reported concordance rates as high as 90 % when EUS-FNA samples contain more than 2000 tumor cells [11].

Most previous reports describing EUS-FNA sampling of pNENs have only focused on sampling adequacy rates, rather than diagnostic accuracy. In addition, no studies have investigated factors related to sampling adequacy for pNENs. The present study, therefore, estimated the EUS-FNA diagnostic accuracy rates in cases of surgically confirmed pNEN and examined various factors related to sampling inadequacy.

Materials and methods

Study design and patient selection

We retrospectively reviewed the data registry of all patients with pancreatic neoplasm who underwent surgical resection preceded by EUS-FNA at Aichi Cancer Center, Nagoya, Japan, between 1998 and 2014.

A total of 698 cases underwent pancreatic resection (including 74 cases with pNEN), 1455 cases underwent EUS-FNA of pancreatic solid masses (including 89 cases with pNEN), and 410 cases underwent both EUS-FNA sampling and surgical resection of the pancreatic neoplasms. Of the cases with dual intervention, 60 cases were included in this study. Forty-nine of these cases were correctly diagnosed by EUS-FNA preoperatively, two cases were misdiagnosed as pNEN by EUS-FNA, and nine surgically confirmed cases of pNEN were not diagnosed by preoperative EUS-FNA. Figure 1 summarizes the patient selection criteria.

This study was approved by the institutional review board of our institution.

EUS-FNA procedures

EUS-FNA was performed using a GF-UC30P (1998-2001), GF-UC240P-AL5 (2001-present), or GF-UCT260-AL5 (2011-present) convex array echoendoscope (Olympus Corporation, Tokyo, Japan) connected to an ultrasound scanning system (Envision Plus; Dornier MedTech, Munich, Germany or SSD-5500, Prosound SSD α-5,10; Hitachi Aloka Medical, Tokyo, Japan), as appropriate according to a previously described methodology [11, 15]. Different types of needles (19-, 22-, or 25G Echo Tip Ultra; Cook Medical, IN, USA, or NA-200H-8022; Olympus Corporation or Expect; Boston Scientific, Tokyo, Japan) were employed for the sampling. The type and size of needle were chosen at the discretion of the endosonographer. We uniformly used negative suction with a 10-mL or 20-mL syringe during all FNA procedures. EUS-FNA was performed by five expert endosonographers (K.Y., K.H., N.M., H.I., S.H.) or under their direct supervision.

Fig. 1 Algorithm for patient inclusion and exclusion
Cytology and immunohistological diagnosis

After spraying the aspirated material onto glass slides, one slide was fixed by air-drying, stained with modified Giemsa stain (Diff-Quik; Kokusai Shiyaku, Kobe, Japan), and reviewed immediately (on-site cytopathological evaluation) by the cytopathologist or cytotechnologist to ensure specimen adequacy. Another slide was fixed by immediate immersion in 95 % alcohol and then stained with Papanicolaou stain. Additional material was obtained from each lesion unless on-site evaluation confirmed the presence of malignant cells or a sufficient number of representative cells from the lesion. Subsequently, the remaining material, as well as the specimen obtained by one more pass, was submitted for cell-block preparation. The cell-block material was processed by fixation in 10 % neutral-buffered formalin solution, then embedded in paraffin to be handled as a routine tissue block. Thin sections from paraffin-embedded cell blocks were cut and stained with hematoxylin and eosin (HE). All diagnoses were confirmed by a combination of characteristic HE features and immunohistochemistry (IHC) showing expression of chromogranin A and/or synaptophysin. In this study, sampling adequacy rate was defined by the proportion of lesions in which adequate material for cytopathological diagnoses could be obtained. Ki67 labeling index (LI) was used for tumor grading. Mitotic count was not performed on our cellblock specimens, because at least 50 high-power fields are required for reliable estimation [8, 16], a requirement that could not be fulfilled in most samples.

Study definitions

EUS-FNA diagnostic accuracy

EUS-FNA diagnosis of pNEN was considered “accurate” when the cell block, including IHC staining results, matched the final diagnosis. In addition, when the cell block including IHC diagnoses was reported as “suspicious” or “consistent”, we included them as accurate diagnoses for pNEN. When cytology and cell-block and/or IHC diagnoses were reported as “suspicious for pNEN”, we included these as “suggestive” for pNEN. When cytology cell-block diagnoses were reported as “atypical” and inadequate for IHC, we included these as “inaccurate diagnoses” for pNEN. Non-diagnostic included “suggestive” and “inaccurate diagnoses”. The criterion standard for “final diagnosis” was the surgical histopathological results for resected specimens alone.

Grading of stromal fibrosis

We evaluated the degree of stromal fibrosis using the maximal section of the resected specimens. We defined “rich fibrosis” when stromal fibrosis occupied more than 30 % of the total tumor area [17].

Magnetic resonance imaging (MRI) for evaluation of fibrosis

The quantity of fibrosis was evaluated by T2-weighted imaging (WI). Cell-rich tumors were depicted as high-

Fig. 2 Representative cases of little and rich stromal fibrosis. a, c, e Images of pNEN with little fibrosis. b, d, f Images of pNEN with rich fibrosis. a, b CT shows strong and moderate hypervascularity in the tumor (arrow). c, d T2-weighted imaging shows a hyper- and hypointense mass in the pancreas head (arrow). e, f Low-power image showing weak and numerous fibrosis

\[ \text{Little fibrosis} \quad \text{Rich fibrosis} \]

\[ \text{CT} \quad \text{MRI T2} \]

Resected specimen
intensity on T2-WI [18], while tumors with more fibrosis were depicted as iso- or low-intensity (Fig. 2). The definition of signal intensity (hyper/iso/hypo) was the result compared with the surrounding parenchyma on T2-WI. The MRI findings were interpreted by mutual discussion between one gastroenterologist (S.H.) and one radiologist (Y.S.). For tumors showing cystic degeneration, we evaluated the MRI findings in the recognizable solid components of the tumor.

Factors affecting accuracy of EUS-FNA for pNEN

Factors affecting the accuracy of EUS-FNA were analyzed using uni- and multivariate analyses. Variables employed for univariate analyses were location of the lesion (pancreatic head, body/tail), size of the lesion (≤10, 10–20 mm, >20 mm), needle size (19G vs. 22G vs. 25G), presence or absence of cystic degeneration, grading of malignancy (G1 or G2/NEC), grading of fibrosis (<30 vs. ≥30%), and period during which EUS-FNA procedure was performed (period I: 1998–2008, comprising the first 30 cases; period II: 2009–2014, comprising the remaining 28 cases). As for needle size, five cases underwent EUS-FNA using two types of needles (22- and 25G needles). These five cases were thus excluded, and the remaining 53 cases were analyzed (19G, n = 3; 22G, n = 46; 25G, n = 5).

Statistical analysis

We used the Chi squared test for univariate analyses, and logistic regression analysis for multivariate analysis. Values of P < 0.05 were regarded as statistically significant. All statistical analyses were undertaken using SPSS version 22 software (IBM, Tokyo, Japan).

Results

Of 410 cases with dual EUS-FNA and surgical resection for a given pancreatic lesion, a total of 60 cases (51% women; mean age, 55.7 ± 14.1 years) who fulfilled our inclusion criteria were identified.

Mean tumor size was 24.1 ± 21.3 mm (range 5–130 mm). Twenty-three tumors (38.3%) were located in the head and 37 (61.6%) in the body and tail. Nineteen lesions (31.6%) displayed a cystic component. Eight patients (13.3%) had liver metastasis. In terms of grading, 58 pNENs were classified as G1, G2, and NEC in 33 (55.0%), 22 (36.6%), and three cases (5.0%), respectively. A definitive diagnosis and grading by surgical resection were achieved in all cases. Table 1 summarizes these characteristics.

### Table 1 Characteristics of the 60 tumors (58 pNEN, 2 non-pNEN) n = 60

| Size (mm) | Mean ± SD | 24.1 ± 21.3 mm |
|----------|-----------|----------------|
| Location | Head      | 23 (38.3%)     |
|          | Body      | 25 (41.6%)     |
|          | Tail      | 12 (20%)       |
| Cystic component | Yes | 19 (31.6%) |
|          | No        | 41 (68.3%)     |
| Distant metastasis | Yes | 8 (13.3%) |
|          | No        | 52 (86.6%)     |
| Grading  | G1        | 33 (55.0%)     |
|          | G2        | 22 (36.6%)     |
|          | NEC       | 3 (5.0%)       |
|          | Non-pNEN  | 2 (3.3%)       |

pNEN pancreatic neuroendocrine neoplasm

Diagnostic yield of EUS-FNA for pNENs

Of the 60 cases, the EUS-FNA diagnosis was classified as non-diagnostic, misdiagnosis, and diagnostic in nine (15.0%), two (3.3%), and 49 cases (81.6%), respectively. In three of nine non-diagnostic cases, because of an insufficient specimen, suitable evaluation of IHC (chromogranin A and/or synaptophysin) could not be performed. However, in the remaining six cases, a diagnosis of pNEN was suspected based on HE staining and/or IHC. The two misdiagnosed tumors were paraganglioma and solid-pseudopapillary neoplasm (SPN) (Table 2). The paraganglioma was misdiagnosed as NET-G2 because the tumor cells were relatively uniform in size and shape, with round nuclei showing slight atypia, with finely dispersed chromatin. IHC staining yielded positive results for chromogranin A and synaptophysin, and negative results for cytokeratin7 and CDX2. Ki67 LI was estimated at 10% (Figure S3). SPN was misdiagnosed as NET-G1 because slightly atypical cells with relatively uniform shape and agglomeration without pseudopapillary structures were seen. IHC staining yielded positive results for chromogranin A and synaptophysin, and negative results for β-catenin and CDX2. Ki67LI was estimated as 1%. IHC for β-catenin was not performed because the results of HE staining, chromogranin A and synaptophysin staining corresponded for pNEN (Figure S4). The remaining 49 cases were diagnosed as pNEN by EUS-FNA and confirmed after surgery. In the TN group that included 350 cases, there was no cases with insufficient material by EUS-FNA. The diagnostic yield of EUS-FNA was:
sensitivity, 84.5 % (49/58); specificity, 99.4 % (350/352); and accuracy, 97.3 % (399/410). Including the six “suggestive” cases as diagnostic, sensitivity was 94.8 % (55/58), specificity was 99.4 % (350/352), and accuracy was 98.7 % (405/410). Details of the diagnostic performance are shown in Table 3.

Factors related to sampling adequacy

To clarify factors affecting the sampling adequacy of EUS-FNA for pNEN, uni- and multivariate analyses were conducted (Table 4). Both uni- and multivariate analyses revealed that tumor location and quantity of stromal fibrosis were significant independent factors affecting sampling adequacy. Lesions that were located in the pancreatic body or tail showed higher sampling adequacy rates than lesions located in the pancreatic head \((P = 0.04; \text{OR} = 10.0)\). Sampling adequacy was lower when the tumor included rich stromal fibrosis \((P = 0.03; \text{OR} = 10.45)\). On the other hand, tumor size, type of needle, grading, presence of cystic component, and study period were not found to be significant factors.

Relationships between T2-weighted images and stromal fibrosis in pNEN

Of the 58 resected pNENs, 30 cases (51.7 %) had undergone MRI preoperatively. Cases showing rich fibrosis (>30 % fibrosis) were more often \((P < 0.001)\) seen as iso- or low-intensity lesions on T2-WI (Table 5). Iso- or low-intensity appearance of pNENs on T2-WI had 100 % sensitivity, 81.8 % specificity, and 96.6 % diagnostic accuracy for the presence of rich fibrosis.

Discussion

A number of reports have described the excellent diagnostic ability of EUS-FNA for pNEN, with sensitivity of 83.3–93 % [4–7]. EUS-FNA is imperative for preoperative diagnosis of pNEN. However, around 10–15 % of cases remain undiagnosed despite EUS-FNA. No previous reports have discussed factors related to inadequate sampling of pNENs by EUS-FNA. Additionally, previous reports have only described sensitivity, without an estimate of true-negative and false-positive cases. This is the first report to calculate the sensitivity, specificity, and accuracy of EUS-FNA for pNENs and to investigate factors affecting the sampling adequacy of EUS-FNA. Surprisingly, we found that tumor size was not a significant predictor of sampling adequacy. In fact, 15 cases (25 %) had tumor size <10 mm (4–10 mm), and these could all be diagnosed by EUS-FNA. The reason for such high yield may be the high cellularity and minimal stromal fibrosis in small tumors. On the other hand, we found that tumor location and the amount of intra-tumoral fibrosis were independent predictors of sampling adequacy. Some previous reports have reached similar conclusions about the influence of tumor location on the diagnostic yield of EUS-FNA [15, 19]. Tumors with rich stromal fibrosis (>30 %) have a lower diagnostic yield on EUS-FNA, compared with tumors with minimal fibrosis \((\text{OR} = 10.45; \ P = 0.03)\). Intra-tumoral fibrosis has been postulated to result from local serotonin production [17, 20, 21], as serotonin has been implicated in fibrogenesis. Carcinoid tumors of the midgut, in which serotonin is the predominant hormone secreted by neoplastic cells, are usually associated with extensive fibrosis [21]. In addition, serotonin has been shown to stimulate fibroblast mitosis in cell cultures [22]. In our cases, IHC for serotonin was not carried out, and whether the fibrosis correlated with local serotonin production remains

---

**Table 2** Detail characteristics of two misdiagnosed cases

| Case | Final diagnosis | Age (years)/Sex | Location | Size (mm) | Contrast-enhanced CT | Calcification | Cystic change | EUS-FNA needle size | CGA<sup>a</sup>/SYP<sup>b</sup> |
|------|----------------|----------------|----------|-----------|----------------------|--------------|--------------|-------------------|------------------|
| 1    | SPN            | 32/M           | Head     | 20        | Hypovascular         | +            | -            | 22G               | +(focal)/+       |
| 2    | Paraganglioma  | 48/F           | Body     | 30        | Hypervascular        | -            | +            | 22G               | ++               |

<sup>a</sup> Chromogranin A  
<sup>b</sup> Synaptophysin

**Table 3** Diagnostic yield of EUS-FNA for pNEN (total cases of dual intervention, \(n = 410\))

| Operation | pNEN | Non-pNEN<sup>a</sup> |
|-----------|------|----------------------|
| EUS-FNA   | 49 (TP) | 2 (FP) |
| Non-pNEN<sup>a</sup> | 9 (FN) | 350 (TN) |

EUS-FNA was classified as non-diagnostic in nine cases, misdiagnosis in two cases, and diagnostic in 49 cases.

pNEN pancreatic neuroendocrine neoplasm, EUS-FNA endoscopic ultrasound-guided fine needle aspiration, TN true negative, FN false negative, FP false positive, TP true positive

<sup>a</sup> Included insufficient material
speculative. How can we improve the diagnosability of pNEN with abundant fibrosis? The addition of T2-WI, which vividly depicts the quantity of fibrosis, will improve the diagnostic yield of pNEN. Most pNENs are hyperintense on T2-WI, but pNEN with abundant stromal fibrosis appears iso- or hypointense [23, 24]. In our series, 81.8% (18/22) of cases with minimal stromal fibrosis showed hyperintensity on T2-WI, whereas 100% (8/8) of cases with rich stromal fibrosis were iso- or hypointense \((P < 0.001)\). We, therefore, recommend not only contrast-enhanced CT, but also MRI without contrast if pNEN is suspected. If an iso- or hypointense lesion is found on T2-WI, pNEN with rich fibrosis should be suspected. In such cases, particular attention must be paid to obtaining adequate tissue during EUS-FNA. Contrast-enhanced EUS (CE-EUS) may represent an attractive option in such cases. CE-EUS plays an important role in finding a specific site within a lesion that would be more suitable for EUS-FNA. Identification of hypervascular sites in such lesions may help avoid sampling rich fibrous areas [25]. Other options are to use high negative-pressure suction techniques in EUS-FNA [26] or a thicker needle [6].

We encountered two false-positive results for pNEN. The final diagnoses in these cases were paraganglioma and SPN. A report by Kari et al. [27] showed that 80% of lesions misclassified as pNEN were actually SPN. Usually, FNA samples demonstrate a pseudopapillary pattern with fibrovascular stalks in SPN. However, in some cases with material crushed during aspiration or inadequate sampling, characteristic features of SPN may not be evident. Additionally, chromogranin A and/or synaptophysin staining is sometimes positive in SPN [28]. Indeed, our case of SPN did not show the classic features such as pseudopapillary pattern with fibrovascular stalks, and positive staining results were obtained for both chromogranin A and synaptophysin. Staining for \(\beta\)-catenin, E-cadherin, and CD10 may be able to better distinguish between pNEN and SPN [29]. Therefore, in cases of suspected SPN, these specialized IHC panels may be required.

The second case misdiagnosed as pNEN actually represented paraganglioma. This patient was asymptomatic before and during EUS-FNA, and even on retrospective review of CT images, the location of the tumor was difficult to identify as retroperitoneal. A case of similar misdiagnosis has been reported [30]. In the case of paraganglioma, EUS-FNA is relatively contraindicated because it may cause a severe hypertensive crisis during EUS-FNA [31]. Most paragangliomas show cystic degeneration, as in our case. When paraganglioma is suspected, meta-iodobenzylguanidine (MIBG) scintigraphy and/or 24-h urine collection for catecholamines, metanephrines, and vanillylmandelic acid is advisable before FNA [32].

Some limitations to this study must be considered. The main shortcomings are the retrospective nature and the potential for bias in selecting patients who were referred for surgery. In this study, of the 89 patients diagnosed as pNEN by EUS-FNA, 40 patients (45%) did not undergo surgery, so these patients were excluded from the study. These cases were inoperable and referred for chemotherapy or follow-up due to patient unwillingness to undergo surgery. In addition, patients in whom pNEN was suspected based on imaging, particularly when small in size (<10 mm) that could not be diagnosed by EUS-FNA, were followed up without surgery, and hence were excluded.

### Table 4

| Variable         | Number | Accuracy (%) | Univariate analysis \(P\) | Multivariate analysis \(P\) | Odds ratio |
|------------------|--------|--------------|--------------------------|-----------------------------|------------|
| Location         |        |              |                          |                             |            |
| Head             | 23     | 69.6         | 0.02                     | 0.04                        | 10.0       |
| Body/tail       | 35     | 94.3         |                          |                             |            |
| Needle\(^a\)    |        |              |                          |                             |            |
| 19G              | 3      | 66.7         | 0.08                     |                             |            |
| 22G              | 46     | 95.6         |                          |                             |            |
| 25G              | 4      | 75.0         |                          |                             |            |
| Tumor size (mm) |        |              |                          |                             |            |
| <10              | 15     | 100          | 0.13                     |                             |            |
| 10–20            | 18     | 83.3         |                          |                             |            |
| >20              | 25     | 76.0         |                          |                             |            |
| Cystic component|        |              |                          |                             |            |
| Present          | 17     | 76.5         | 0.24                     |                             |            |
| Absent           | 41     | 87.8         |                          |                             |            |
| Grading          |        |              |                          |                             |            |
| G1               | 33     | 87.9         | 0.32                     |                             |            |
| G2 or NEC        | 25     | 80.0         |                          |                             |            |
| Stromal fibrosis (%)|    |              |                          |                             |            |
| <30              | 42     | 92.9         | 0.01                     | 0.03                        | 10.45      |
| >30              | 16     | 62.5         |                          |                             |            |
| Period           |        |              |                          |                             |            |
| 1998–2008        | 30     | 80.0         | 0.47                     |                             |            |
| 2009–2014        | 28     | 89.3         |                          |                             |            |

\(^a\) Five patients in whom more than one needle was used were excluded

### Table 5

| Stromal fibrosis | MRI-T2 WI     |                  |
|------------------|---------------|------------------|
|                  | Low-iso intensity | High intensity |
| Little           | 4 (13.3 %)     | 18 (60 %)        |
| Rich             | 8 (26.6 %)     | 0 (0 %)          |

We also encountered two false-positive results for pNEN. The final diagnoses in these cases were paraganglioma and SPN. A report by Kari et al. [27] showed that 80% of lesions misclassified as pNEN were actually SPN. Usually, FNA samples demonstrate a pseudopapillary pattern with fibrovascular stalks in SPN. However, in some cases with material crushed during aspiration or inadequate sampling, characteristic features of SPN may not be evident. Additionally, chromogranin A and/or synaptophysin staining is sometimes positive in SPN [28]. Indeed, our case of SPN did not show the classic features such as pseudopapillary pattern with fibrovascular stalks, and positive staining results were obtained for both chromogranin A and synaptophysin. Staining for \(\beta\)-catenin, E-cadherin, and CD10 may be able to better distinguish between pNEN and SPN [29]. Therefore, in cases of suspected SPN, these specialized IHC panels may be required.

The second case misdiagnosed as pNEN actually represented paraganglioma. This patient was asymptomatic before and during EUS-FNA, and even on retrospective review of CT images, the location of the tumor was difficult to identify as retroperitoneal. A case of similar misdiagnosis has been reported [30]. In the case of paraganglioma, EUS-FNA is relatively contraindicated because it may cause a severe hypertensive crisis during EUS-FNA [31]. Most paragangliomas show cystic degeneration, as in our case. When paraganglioma is suspected, meta-iodobenzylguanidine (MIBG) scintigraphy and/or 24-h urine collection for catecholamines, metanephrines, and vanillylmandelic acid is advisable before FNA [32]. Some limitations to this study must be considered. The main shortcomings are the retrospective nature and the potential for bias in selecting patients who were referred for surgery. In this study, of the 89 patients diagnosed as pNEN by EUS-FNA, 40 patients (45%) did not undergo surgery, so these patients were excluded from the study. These cases were inoperable and referred for chemotherapy or follow-up due to patient unwillingness to undergo surgery. In addition, patients in whom pNEN was suspected based on imaging, particularly when small in size (<10 mm) that could not be diagnosed by EUS-FNA, were followed up without surgery, and hence were excluded.
from our study. This may carry an unavoidable selection bias. Therefore, as shown in Table 4, the diagnostic performance of EUS-FNA was 100% for pNENs <10 mm.

The negative-pressure suction technique are also one of the important factors influencing the diagnostic performance. To date, few randomized, controlled trials have examined negative-pressure suction techniques. Puri et al. [33] concluded that the use of negative pressure did not improve diagnostic accuracy, but Kudo et al. [26] mentioned that a high negative-pressure suction technique is superior to normal negative-pressure suction in terms of obtaining sufficient material for histological diagnosis. The necessity for negative-pressure suction technique remains controversial [34]. Consideration of this factor as a variable potentially affecting sampling adequacy would have been preferable, but the use of negative-pressure suction with a 10- or 20-mL syringe for almost all cases meant that such evaluation could not be performed.

As for needle size, Sakamoto et al. [35] reported that a 25G needle is less adequate for histological diagnosis compared with other needles, and Larghi et al. [6] argued that 19G is safe, feasible, and highly accurate for both diagnosis and Ki-67 determination. Needle size is thus an important factor affecting the accuracy of EUS-FNA for pNEN.

In 53 cases (excluding the five patients for whom both 22G and 25G needles were used), comparisons were made between 19G, 22G, and 25G needles, revealing no significant differences. However, the small number of cases makes reaching any firm conclusions difficult, and further studies are needed.

The strength of this study was that this is the first report to compare results of EUS-FNA with surgery as the gold standard, along with a complete description of diagnostic performance.

In conclusion, EUS-FNA offers a high accuracy for pNEN. However, tumor location in the pancreatic head and tumors with rich stromal fibrosis were associated with reduced sampling adequacy of EUS-FNA. We recommend the addition of T2-WI in all cases of suspected pNEN before EUS-FNA and use of a variety of complementary diagnostic modalities when the lesion appears iso- or hypointense on MRI.

Acknowledgments This work was supported in part by the National Cancer Center Research and Development Fund (25-A-3) and JSPS KAKENHI Grant Number 26461041 (N.M.) and by the Research for Promotion of Cancer Control Programmes from Japan Agency for Medical Research and Development, AMED (N.M.). We also wish to thank Dr. Yozo Sato for helping with the interpretation of MRI.

Compliance with ethical standards

Conflict of interest N.M. has received research funding from Taiho Pharmaceutical and Takeda Bio Development Center Ltd., and speaking honoraria from Taiho Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Yakult Honsha Novartis, Phizer and Kyowa-Hakko Kirin, and speakers’ bureau with Taiho Pharmaceutical Co. Ltd.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766–73.
2. Attili F, Capurso G, Vanella G, et al. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis. 2014;46:9–17.
3. Puli SR, Kalva N, Bechtold ML, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis. World J Gastroenterol. 2013;19:3678–84.
4. Gornals J, Varas M, Catalá I, et al. Definitive diagnosis of neuroendocrine tumors using fine-needle aspiration-puncture guided by endoscopic ultrasonography. Rev Esp Enferm Dig. 2011;103:123.
5. Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–93.
6. Larghi A, Capurso G, Carnuccio A, et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc. 2012;76:570–7.
7. Atiq M, Bhutani MS, Bektas M, et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2012;57:791–800.
8. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010.
9. Carlinfante G, Baccarini P, Berretti D, et al. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. Virchows Arch. 2014;465:49–55.
10. Farrell JM, Pang JC, Kim GE, et al. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol. 2014;122:770–8.
11. Hasegawa T, Yamao K, Hijjoka S, et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy. 2014;46:32–8.
12. Remes SM, Tuominen VI, Helin H, et al. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol. 2012;36:1359–63.
13. Unno J, Kanno A, Masamune A, et al. The usefulness of endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of pancreatic neuroendocrine tumors based on the World Health Organization classification. Scand J Gastroenterol. 2014;49:1367–74.
14. Weynand B, Borbath I, Bernard V, et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle
15. Haba S, Yamao K, Bhata V, et al. Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions: a Japanese large single center experience. J Gastroenterol. 2013;48:973–81.

16. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.

17. McCall CM, Shi C, Klein AP, et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Hum Pathol. 2012;43:1169–76.

18. Reznek RH. CT/MRI of neuroendocrine tumours. Cancer Imaging. 2006;6:S163–77.

19. Nakai Y, Isayama H, Chang KJ, et al. Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci. 2014;59:1578–85.

20. Ro C, Chai W, Victoria EY, et al. Pancreatic neuroendocrine tumors: biology, diagnosis, and treatment. Chin J Cancer. 2013;32:312–24.

21. Shi C, Siegelman SS, Kawamoto S, et al. Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production? Radiology. 2010;257:107–14.

22. Lee SL, Wang WW, Lanzillo JJ, et al. Serotonin produces both hyperplasia and hyper trophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol. 1994;266:L46–52.

23. Thoeni RF, Mueller-Lisse UG, Chan R, et al. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000;214:483–90.

24. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinico-pathologic correlation. Radiographics. 2010;30:1445–64.

25. Kitano M, Kamata K, Imai H, et al. Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. Dig Endosc. 2015;27(Suppl 1):60–7.

26. Kudo T, Kawakami H, Hayashi T, et al. High and low negative pressure suctions in EUS-guided fine-needle tissue acquisition by using 25-gauge needles: a multicenter, prospective, randomized, controlled trial. Gastrointest Endosc. 2014;80:1030–7.

27. Hooper K, Mukhtar F, Li S, et al. Diagnostic error assessment and associated harm of endoscopic ultrasound-guided fine-needle aspiration of neuroendocrine neoplasms of the pancreas. Cancer Cytopathol. 2013;121:653–60.

28. Burford H, Baloch Z, Liu X, et al. E-cadherin/beta-catenin and CD10: a limited immunohistochemical panel to distinguish pancreatic endocrine neoplasm from solid pseudopapillary neoplasm of the pancreas on endoscopic ultrasound-guided fine-needle aspirates of the pancreas. Am J Clin Pathol. 2009;132:831–9.

29. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg. 2005;200:965–72.

30. Gane RL, Castro ACF, Colaiacovo R, et al. Endoscopic ultrasound-guided fine needle aspiration for the diagnosis of non-functional paragangliomas: a case report and review of the literature. Endosc Ultrasound. 2012;1:108–9.

31. Kubota K, Kato S, Mawatari H, et al. Risky endoscopic ultrasonography-guided fine-needle aspiration for asymptomatic retroperitoneal tumors. Dig Endosc. 2010;22:144–6.

32. Baguet JP, Hammer L, Tremel F, et al. Metastatic phaeochromocytoma: risks of diagnostic needle puncture and treatment by arterial embolisation. J Hum Hypertens. 2001;15:209–11.

33. Puri R, Vilmann P, Saftoiu A, et al. Randomized controlled trial of endoscopic ultrasound-guided fine-needle sampling with or without suction for better cytological diagnosis. Scand J Gastroenterol. 2009;44:499–504.

34. Kawakami H, Kubota Y, Sakamoto N. Endoscopic ultrasound-guided fine-needle aspiration of gastrointestinal and pancreatic tumors: is negative pressure helpful or does it suck? Dig Dis Sci. 2015; doi:10.1007/s10620-015-3920-5.

35. Sakamoto H, Kitano M, Komaki T, et al. Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses. J Gastroenterol Hepatol. 2009;24:384–90.